Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy

Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) is one of the well-recognized extranodal lymphomas commonly addicted to the B-cell receptor-MYD88 superpathway. We aimed to describe the genomic changes in a patient who progressed through treatment with ibrutinib, a Bruton’s tyr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of molecular sciences 2018-06, Vol.19 (6), p.1758
Hauptverfasser:	Fox, Lucy C, Yannakou, Costas K, Ryland, Georgina, Lade, Stephen, Dickinson, Michael, Campbell, Belinda A, Prince, Henry Miles
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged, 80 and over Antineoplastic Agents - administration & dosage Antineoplastic Agents - therapeutic use Apoptosis B-cell lymphoma B-cell receptor Bruton's tyrosine kinase CARD Signaling Adaptor Proteins - genetics Case Report Disease Progression Drug resistance Enzyme inhibitors Female Genomic analysis Genomic Instability Guanylate Cyclase - genetics Heavy chains Humans I-kappa B Proteins - genetics Immunoglobulins Inhibitor drugs Interferon Regulatory Factors - genetics Leg Lymph nodes Lymphatic Metastasis Lymphocytes B Lymphoma Lymphoma, Large B-Cell, Diffuse - drug therapy Lymphoma, Large B-Cell, Diffuse - genetics Lymphoma, Large B-Cell, Diffuse - pathology Molecular modelling Mutation MyD88 protein NF-κB protein Patients Pretreatment Protein-tyrosine kinase Proteins Proto-Oncogene Proteins - genetics Proto-Oncogene Proteins c-bcl-2 - genetics Pyrazoles - administration & dosage Pyrazoles - therapeutic use Pyrimidines - administration & dosage Pyrimidines - therapeutic use Radiation therapy Skin diseases Skin Neoplasms - drug therapy Skin Neoplasms - genetics Skin Neoplasms - pathology Targeted cancer therapy Tumors Tyrosine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!